Sarepta Therapeutics, Inc. SRPT Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Sarepta Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The official record: Sarepta Therapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Sarepta Therapeutics, Inc.'s operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Sarepta Therapeutics, Inc.'s operating cash flow?
- Sarepta Therapeutics, Inc. (SRPT) reported operating cash flow of -$202.68M in Q1 2026.
- How has Sarepta Therapeutics, Inc.'s operating cash flow changed year-over-year?
- Sarepta Therapeutics, Inc.'s operating cash flow increased by 65.3% year-over-year, from -$583.44M to -$202.68M.
- What is the long-term trend for Sarepta Therapeutics, Inc.'s operating cash flow?
- Over 2 years (2021 to 2023), Sarepta Therapeutics, Inc.'s operating cash flow has grown at a 6.3% compound annual growth rate (CAGR), from -$443.17M to -$500.99M.
- What does operating cash flow mean?
- Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.